A wart is a small growth on the skin caused by the human papilloma virus, HPV. Warts are contagious and can easily be transferred to other people and other parts of the body. As many as 10% of the total population are suffering from warts and among children, as many as 1 in 3 are affected. EndWarts is a powerful wart treatment, which effectively dries out warts on hands, feet, elbows and knees. It contains formic acid and the unique solution penetrates the wart deep down to the roots and helps the body to effectively dry out and reject the wart. EndWarts is easy to use and the treatment only takes a few seconds once a week until the wart is gone. The solution is absorbed directly into the wart and leaves no scars. EndWarts is now also available in a convenient pen device for a safe and precise application. Further life cycle projects are ongoing to strengthen the brand and the position in the market.
Dose and administration: Apply hydrocortisone cream to the affected area as a thin film 2 to 4 times daily depending on the severity of the condition. It is not likely other drugs you take orally or inject will have an effect on topically applied hydrocortisone. But many drugs can interact with each other. Tell your doctor all prescription and over-the-counter medications and supplements you use. During pregnancy, hydrocortisone should be used only when prescribed. Infants born to mothers who have been using this medication for an extended period of time may have hormone problems. Tell your doctor if you notice symptoms such as persistent nausea/vomiting, severe diarrhea, or weakness in your newborn. This medication passes into breast milk. However, this drug is unlikely to harm a nursing infant. Consult your doctor before breast-feeding.
References: 1. Bikowski J, Pillai R, Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol . 2006;5(2):125-130. 2. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol . 2005; 53(1 Suppl 1):s50-s58. 3. US Food and Drug Administration NDA 017765. Promius Pharma, LLC, Princeton, NJ: Aug 1977. 4. Rosenthal AL. Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis . 1980;25(1):96-98. 5. Kircik LH. A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay. J Drugs Dermatol . 2014;13(5):582-585. 6. Cloderm [package insert]. Princeton, NJ: Promius Pharma, LLC; 2017.